Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 44Leukemia, Lymphocytic, Chronic, B-Cell 16Myelodysplastic Syndromes 7Leukemia, Biphenotypic, Acute 5Burkitt Lymphoma 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 3Myeloproliferative Disorders 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Blast Crisis 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, B-Cell 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Hairy Cell 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 15Rituximab 12fludarabine 7Specimen Handling 7Magnetic Resonance Spectroscopy 7fludarabine phosphate 6obinutuzumab 5X-Rays 5Phantoms, Imaging 5Biopsy 5polatuzumab vedotin 4pembrolizumab 4ibrutinib 4Whole-Body Irradiation 4Prednisone 4Nuclear Medicine Department, Hospital 4Mycophenolic Acid 4Lenalidomide 4Cyclosporine 4venetoclax 3tocilizumab 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Leukapheresis 3Gemcitabine 3Etoposide 3Doxorubicin 3Dexamethasone 3Busulfan 3zanubrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × venetoclax × 30 days × Clear all
NCT03223610 2026-05-22

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
155 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03844048 2026-05-13

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

AbbVie

Phase 3 Active not recruiting
165 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05529069 2026-05-05

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡